Mergers & Acquisitions ·
BioLife Solutions filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) on August 3, 2026, to furnish an email…
BLFSBiolife Solutions Inc
BioLife Solutions filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) on August 3, 2026, to furnish an email from Chairman and CEO Rod Roderick de Greef circulating a video message from Repligen Corporation President and CEO Olivier Loeillot. The communication provides additional information regarding the previously announced Agreement and Plan of Merger dated July 21, 2026, under which Repligen will acquire BioLife through a two-step merger process. Repligen management emphasized that the transaction remains subject to regulatory and shareholder approvals, with closing expected in the fourth quarter of 2026, while both entities continue to operate independently. This filing serves as a disclosure of forward-looking statements and strategic rationale for the acquisition. BioLife Solutions operates in the biotechnology industry, providing cell processing tools and biopreservation media.